Published in
Wiley, British Journal of Dermatology, 1(188), p. 146-148, 2022
DOI: 10.1093/bjd/ljac008
Links
Tools
Interleukin-13 inhibition by tralokinumab reduces inducible T-cell costimulator-positive innate lymphoid cells in skin lesions of atopic dermatitis
Journal article published in 2022 by
Toshiaki Kogame 
,
Satoru Yonekura ,
Paola Lovato,
Masahiro Hirata,
Riko Takimoto-Ito,
Tomoya Takegami,
Takayoshi Komatsu-Fujii ,
Naotomo Kambe ,
Takashi Nomura ,
Mads A. Røpke,
Kenji Kabashima
,
Satoru Yonekura ,
Paola Lovato,
Masahiro Hirata,
Riko Takimoto-Ito,
Tomoya Takegami,
Takayoshi Komatsu-Fujii ,
Naotomo Kambe ,
Takashi Nomura ,
Mads A. Røpke,
Kenji Kabashima
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Despite the low frequency of skin ILCs and the limited number of samples analyzed in this study, our data indicate that ICOS+ ILCs express IL-13Rα1 and that the density of ICOS+ ILCs decreased four weeks after initiation of treatment with tralokinumab.